International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

ABSTRACT Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). Background: The Movement Disorder Society Evidence‐Based Medicine Committee recommendations for treatments of PD were first published i...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Movement disorders Ročník 33; číslo 8; s. 1248 - 1266
Hlavní autoři:	Fox, Susan H., Katzenschlager, Regina, Lim, Shen‐Yang, Barton, Brandon, de Bie, Rob M. A., Seppi, Klaus, Coelho, Miguel, Sampaio, Cristina
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.08.2018
Témata:	amantadine anticholinergics Antiparkinson Agents catechol‐O‐methyl transferase inhibitors clozapine complementary therapies Deep Brain Stimulation dopamine agonists Evidence-Based Medicine exercise Humans International Cooperation levodopa monoamine oxidase inhibitors neurosurgery occupational therapy Parkinson Disease - physiopathology Parkinson Disease - therapy Parkinson's disease physical therapy Physical Therapy Modalities randomized controlled trial Societies, Scientific - standards speech therapy Parkinson's disease monoamine oxidase inhibitors speech therapy catechol-O-methyl transferase inhibitors exercise amantadine dopamine agonists deep brain stimulation randomized controlled trial complementary therapies levodopa clozapine physical therapy neurosurgery anticholinergics evidence-based medicine occupational therapy
ISSN:	0885-3185, 1531-8257, 1531-8257
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	ABSTRACT Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). Background: The Movement Disorder Society Evidence‐Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016. Methods: Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported. Results: A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise‐based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful. Conclusions: The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society
Bibliografie:	Nothing to report. Relevant conflicts of interests/financial disclosures ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0885-3185 1531-8257 1531-8257
DOI:	10.1002/mds.27372